Charles M Rudin

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer
    Sridhar Mani
    Department of Medicine, Section of Hematology Oncology, Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 8:1042-8. 2002
  2. ncbi request reprint Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers
    P Seshidhar Reddy
    Neotropix, Inc, 351 Phoenixville Pike, Malvern, PA 19355, USA
    J Natl Cancer Inst 99:1623-33. 2007
  3. pmc Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer
    Nicholas W Choong
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60615, USA
    J Thorac Oncol 3:59-67. 2008
  4. pmc Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center, David H Koch Cancer Research Building, Suite 544, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:870-6. 2008
  5. ncbi request reprint Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H Koch Cancer Research Building, Room 544, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:1119-27. 2008
  6. pmc Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, Baltimore, MD 21231, USA
    J Thorac Oncol 8:619-23. 2013
  7. pmc Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    Nat Genet 44:1111-6. 2012
  8. pmc Vismodegib
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Cancer Res 18:3218-22. 2012
  9. pmc Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building 2, Room 544, 1550 Orleans Street, Baltimore, MD 21231, USA
    Clin Cancer Res 18:3163-9. 2012
  10. ncbi request reprint Novel systemic therapies for small cell lung cancer
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Natl Compr Canc Netw 6:315-22. 2008

Detail Information

Publications70

  1. ncbi request reprint Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer
    Sridhar Mani
    Department of Medicine, Section of Hematology Oncology, Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 8:1042-8. 2002
    ..Our study warrants further exploration of efficacy in a Phase II and/or Phase III clinical trial setting...
  2. ncbi request reprint Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers
    P Seshidhar Reddy
    Neotropix, Inc, 351 Phoenixville Pike, Malvern, PA 19355, USA
    J Natl Cancer Inst 99:1623-33. 2007
    ..However, the treatment of metastatic disease with oncolytic viruses has been challenging due to the inactivation of viruses by components of human blood and/or to inadequate tumor selectivity...
  3. pmc Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer
    Nicholas W Choong
    Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL 60615, USA
    J Thorac Oncol 3:59-67. 2008
    ....
  4. pmc Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center, David H Koch Cancer Research Building, Suite 544, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:870-6. 2008
    ..bcl-2 has been implicated as a key factor in SCLC oncogenesis and chemotherapeutic resistance...
  5. ncbi request reprint Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H Koch Cancer Research Building, Room 544, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:1119-27. 2008
    ..To assess the pharmacogenomic and pharmacokinetic determinants of skin rash and diarrhea, the two primary dose-limiting toxicities of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib...
  6. pmc Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, Baltimore, MD 21231, USA
    J Thorac Oncol 8:619-23. 2013
    ..On the basis of these data, we performed an exploratory clinical study, assessing the efficacy of itraconazole with cytotoxic chemotherapy in the treatment of patients with advanced lung cancer...
  7. pmc Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    Nat Genet 44:1111-6. 2012
    ..These data provide an in-depth view of the spectrum of genomic alterations in SCLC and identify several potential targets for therapeutic intervention...
  8. pmc Vismodegib
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Cancer Res 18:3218-22. 2012
    ..The mechanism of action, preclinical and clinical data, and potential utility in other disease contexts are reviewed here...
  9. pmc Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building 2, Room 544, 1550 Orleans Street, Baltimore, MD 21231, USA
    Clin Cancer Res 18:3163-9. 2012
    ..The primary objectives of this phase IIa study included safety at the recommended phase II dose and preliminary, exploratory efficacy assessment in patients with recurrent and progressive SCLC after at least one prior therapy...
  10. ncbi request reprint Novel systemic therapies for small cell lung cancer
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Natl Compr Canc Netw 6:315-22. 2008
    ..Novel therapeutic approaches based on advances in understanding of the biology of SCLC have the potential to radically change the outlook for patients with this disease...
  11. doi request reprint Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    N Engl J Med 361:1173-8. 2009
    ....
  12. pmc Lung cancer in never smokers: a call to action
    Charles M Rudin
    Johns Hopkins University, Baltimore, Maryland 21231, USA
    Clin Cancer Res 15:5622-5. 2009
    ..This CCR Focus summarizes recent data, identifies knowledge deficits, and suggests future research directions with regard to this critically important subset of lung cancer patients...
  13. pmc Lung cancer in never smokers: molecular profiles and therapeutic implications
    Charles M Rudin
    Johns Hopkins University School of Medicine, David H Koch Cancer Research Building, Room 544, 1550 Orleans Street, Baltimore, MD 21231, USA
    Clin Cancer Res 15:5646-61. 2009
    ..Focused analysis of molecular carcinogenesis in lung cancers in never smokers is needed, and may provide additional biologic insight with therapeutic implications for lung cancers in both ever smokers and never smokers...
  14. doi request reprint Beyond the scalpel: targeting hedgehog in skin cancer prevention
    Charles M Rudin
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Prev Res (Phila) 3:1-3. 2010
    ..This new study of cyclooxygenase inhibition, together with recent data on the efficacy of hedgehog pathway inhibition, offers new hope for patients at a high risk for basal cell cancer...
  15. doi request reprint Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features
    Charles M Rudin
    Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 17:888-95. 2011
    ..We conducted a first-in-human, first-in-class phase I clinical trial of this agent in patients with cancers with neuroendocrine features, including small cell lung cancer...
  16. doi request reprint Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H Koch Cancer Research Building 2, 1550 Orleans St, Rm 544, Baltimore, MD 21231, USA
    J Clin Oncol 29:1075-82. 2011
    ..We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced or metastatic non-small-cell lung cancer (NSCLC)...
  17. ncbi request reprint Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study
    Charles M Rudin
    The University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 10:7244-51. 2004
    ..Liposomal formulation may promote better intratumoral AON delivery and inhibit degradation in vivo. We conducted the first clinical evaluation of this concept using a liposomal AON complementary to the c-raf-1 proto-oncogene (LErafAON)...
  18. ncbi request reprint Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
    Charles M Rudin
    University of Chicago, Illinois, USA
    J Clin Oncol 22:1110-7. 2004
    ..A dose-finding study was performed evaluating the combination of G3139, carboplatin, and etoposide in patients with previously untreated extensive stage SCLC...
  19. pmc Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer
    Rosalyn A Juergens
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cancer Discov 1:598-607. 2011
    ....
  20. pmc Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer
    Rebekah L Zinn
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD, USA
    Mol Cancer 12:16. 2013
    ..Chemotherapy and targeted therapies, including the Bcl-2 inhibitor ABT-737, may induce tumor cell autophagy. Autophagy can promote survival of cancer cells under stress and comprise a pathway of escape from cytotoxic therapies...
  21. ncbi request reprint Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin
    David J VanderWeele
    Committee on Cancer Biology, University of Chicago, Illinois, USA
    Mol Cancer Ther 3:1605-13. 2004
    ..These data provide insight into potentially synergistic combinations of anticancer therapies...
  22. pmc Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer
    Christine L Hann
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Cancer Res 68:2321-8. 2008
    ..Taken together, these data have specific implications for the clinical development of Bcl-2 inhibitors for SCLC and broader implications for the testing of novel anticancer strategies in relevant preclinical models...
  23. ncbi request reprint Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer
    Nicholas W Choong
    Section of Hematology Oncology and Phase II Network, University of Chicago Medical Center, Chicago, Illinois 60615, USA
    J Thorac Oncol 1:245-51. 2006
    ..This study was performed to evaluate the tolerability and efficacy of temozolomide and irinotecan as a second-line regimen in recurrent/metastatic non-small cell lung cancer (NSCLC)...
  24. pmc DNA cleavage and Trp53 differentially affect SINE transcription
    Christy R Hagan
    Committee on Cancer Biology and Department of Medicine, University of Chicago, Chicago, IL, USA
    Genes Chromosomes Cancer 46:248-60. 2007
    ..Together these data support a model in which initial DNA damage can trigger genomic instability due to SINE activation, a response which may be amplified in cancer cells lacking functional TP53...
  25. pmc Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer
    Timothy F Burns
    Departments of 1Oncology and 2Radiation Oncology and Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Mol Cancer Res 11:329-38. 2013
    ..Together these findings suggest that silencing of TWIST1 in oncogene driver-dependent NSCLCs represents a novel and promising therapeutic strategy...
  26. pmc Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer
    Blake T Aftab
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Res 71:6764-72. 2011
    ..Based on these observations, we have initiated a randomized phase II study comparing the efficacy of standard cytotoxic therapy with or without daily oral itraconazole in patients with recurrent metastatic NSCLC...
  27. ncbi request reprint Management of small-cell lung cancer: incremental changes but hope for the future
    Christine L Hann
    Upper Aerodigestive Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Oncology (Williston Park) 22:1486-92. 2008
    ..The past 2 decades have been marked by an improved understanding of SCLC biology, and these discoveries are reflected in the number and diversity of novel therapies entering early-phase testing in this disease...
  28. ncbi request reprint Survival after community diagnosis of early-stage non-small cell lung cancer
    Norma F Kanarek
    Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Md Electronic address
    Am J Med 127:443-9. 2014
    ..Our objective was to assess the contribution of diagnosis to first surgery interval to survival among patients diagnosed in the community with early-stage non-small cell lung cancer...
  29. doi request reprint Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Detroit, Michigan Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 17:2502-11. 2011
    ..This phase I trial assessed GDC-0449 treatment in patients with solid tumors refractory to current therapies or for which no standard therapy existed...
  30. ncbi request reprint Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come
    Malcolm V Brock
    Division of Thoracic Surgery, Department of Surgery, The Johns Hopkinds Medical Institutions, Baltimore, MD, USA
    J Thorac Cardiovasc Surg 129:64-72. 2005
    ..Although resection is not the standard of care in treating small cell lung cancer, new platinum drugs and modern staging have allowed the role of surgery to be reevaluated...
  31. ncbi request reprint Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate
    David J VanderWeele
    Committee on Cancer Biology, University of Chicago, Chicago, IL, USA
    Mol Cancer Res 3:635-44. 2005
    ..We conclude that mTOR activity can promote resistance through multiple mechanisms independent of maintained glycolytic rate...
  32. pmc Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo
    Chandrashekhar D Kamat
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD 21287, USA
    Mol Cancer Ther 12:405-15. 2013
    ..This is the first demonstration of TP53 gene therapy in SCLC using nonviral polymeric nanoparticles. This technology may have general applicability as a novel anticancer strategy based on restoration of tumor suppressor gene function...
  33. pmc Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer
    Joelle Hillion
    Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Mol Cancer Res 7:1803-12. 2009
    ..Our findings suggest an important role for MMP-2 in transformation mediated by HMGA1 in large-cell, undifferentiated lung carcinoma and support the development of strategies to target this pathway in selected tumors...
  34. ncbi request reprint Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study
    Philip C Hoffman
    Department of Medicine, The University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Lung Cancer 38:65-71. 2002
    ..5 months. We conclude that the combination of carboplatin, vinorelbine, and radiotherapy is feasible at these doses. It may be a useful alternative for patients not able to tolerate cisplatin-based therapy...
  35. ncbi request reprint A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer
    Jerome D Winegarden
    The Department of Medicine, Section of Hematology and Oncology, University of Chicago Medical Center, University of Chicago Cancer Center and the Phase II Network, 5841 S Maryland Avenue MC2115, Chicago, IL 60637, USA
    Lung Cancer 39:191-6. 2003
    ..Bryostatin-1 is a macrocyclic lactone, which exhibits pleiotropic biological effects via protein kinase C and has shown preclinical synergy with paclitaxel for enhanced tumor cell apoptosis...
  36. pmc The twist box domain is required for Twist1-induced prostate cancer metastasis
    Rajendra P Gajula
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 1550 Orleans Street, CRB2 Rm 406, Baltimore, MD 21231
    Mol Cancer Res 11:1387-400. 2013
    ..Implications: Targeting the Twist box domain of Twist1 may effectively limit prostate cancer metastatic potential...
  37. pmc ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer
    Rebekah L Zinn
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Mol Cancer Ther 12:1131-9. 2013
    ..Taken together our data support IGF-1R inhibition as a viable treatment strategy for a defined subset of SCLC and suggest that low pretreatment levels of phospho-ERK may be indicative of sensitivity to this therapeutic approach...
  38. pmc A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro
    Vincent C Daniel
    Department of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 69:3364-73. 2009
    ..Such changes in gene expression may be a common feature of many cancer cell culture systems, with functional implications for the use of such models for preclinical drug development...
  39. ncbi request reprint Rapamycin rescues ABT-737 efficacy in small cell lung cancer
    Eric E Gardner
    Authors Affiliations Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine Departments of Oncology and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkAuthors Affiliations Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine Departments of Oncology and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer Res 74:2846-56. 2014
    ..These data have direct translational implications for SCLC clinical trials...
  40. doi request reprint Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report
    Patrick M Forde
    Departments of Medical Oncology, Surgery, and Pathology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland and Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland
    J Thorac Oncol 9:414-8. 2014
    ..We report the largest series to date of 49 patients with locally advanced or metastatic pulmonary carcinoid...
  41. doi request reprint Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers
    Jing Zeng
    Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 2410, USA
    Int J Radiat Oncol Biol Phys 86:143-9. 2013
    ..Whether Hedgehog inhibition can affect radiation efficacy in vivo has not been reported...
  42. pmc The future of epigenetic therapy in solid tumours--lessons from the past
    Nilofer Azad
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Nat Rev Clin Oncol 10:256-66. 2013
    ..If so, optimal use of these known agents might also pave the way for the introduction of other agents that target the epigenome...
  43. pmc Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer
    J T Poirier
    Sidney Kimmel Compre hensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Natl Cancer Inst 105:1059-65. 2013
    ..This classifier demonstrates a sensitivity of .89, specificity of .92, and accuracy of .91. The NEUROD1 to ASCL1 ratio may serve as a predictive biomarker of SVV-001 efficacy. ..
  44. doi request reprint Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001
    John T Poirier
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
    J Gen Virol 93:2606-13. 2012
    ..These infectious clones will be of substantial value in further characterizing the biology of this virus and as a backbone for the generation of additional oncolytic derivatives...
  45. doi request reprint Crizotinib in the treatment of non-small-cell lung cancer
    Patrick M Forde
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Expert Opin Pharmacother 13:1195-201. 2012
    ..Emerging data suggest that crizotinib may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the MET oncogene, or translocation of the ROS1 oncogene...
  46. pmc Lung cancer in never smokers: clinical epidemiology and environmental risk factors
    Jonathan M Samet
    Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 15:5626-45. 2009
    ..However, a large fraction of lung cancers occurring in never smokers cannot be definitively associated with established environmental risk factors, highlighting the need for additional epidemiologic research in this area...
  47. ncbi request reprint Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
    Federico Innocenti
    Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    J Clin Oncol 22:1382-8. 2004
    ..UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the glucuronidation of the active metabolite SN-38. This study prospectively evaluated the association between the prevalence of severe toxicity and UGT1A1 genetic variation...
  48. ncbi request reprint Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance
    Charles M Rudin
    Department of Medicine and Committee on Cancer Biology, University of Chicago, Chicago, Illinois 60637, USA
    Cancer Res 63:312-8. 2003
    ..Inhibition of glutathione synthesis or modulation of glutathione stores in tumors that overexpress Bcl-2 may comprise a novel anticancer strategy...
  49. pmc SVF1 regulates cell survival by affecting sphingolipid metabolism in Saccharomyces cerevisiae
    Jennifer L Brace
    Johns Hopkins University, Baltimore, Maryland 21231, USA
    Genetics 175:65-76. 2007
    ..Together, these data suggest that compartmentalized generation of distinct intracellular subsets of sphingoid bases may be critical for activation of signaling pathways that control cell growth and survival...
  50. ncbi request reprint Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer
    Christine L Hann
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Cancer Research, Building 2, Baltimore, MD 21231, USA
    Trends Mol Med 13:150-7. 2007
    ....
  51. pmc A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists
    Venugopal Chenna
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Mol Cancer Ther 11:165-73. 2012
    ..No demonstrable hematologic or biochemical abnormalities were observed with NanoHHI administration. NanoHHI should be amenable to clinical translation in settings where tumors acquire mutational resistance to current Smo antagonists...
  52. pmc Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo
    Joyce Osanyingbemi-Obidi
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Mol Cancer Res 9:1746-54. 2011
    ..Distinct Notch family members may have different and potentially opposing activities in oncogenesis, and targeted inhibition of individual Notch family members may be a more effective anticancer strategy than global pathway suppression...
  53. ncbi request reprint Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress in Saccharomyces cerevisiae
    Jennifer L Brace
    The Committee on Cancer Biology, University of Chicago, Chicago, IL 60637, USA
    Yeast 22:641-52. 2005
    ..Our data are consistent with previous observations suggesting a key role of oxidative stress response in mammalian apoptotic regulation and validate the use of S. cerevisiae as a model for studying programmed cell death...
  54. ncbi request reprint ALK-targeted therapy for lung cancer: ready for prime time
    Hatim Husain
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Oncology (Williston Park) 25:597-601. 2011
    ..Taken together, these data describe a trajectory of research progress from basic discovery science to real-world implementation that should serve as a model for future integration of preclinical and clinical therapeutic research...
  55. ncbi request reprint Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo
    Robyn Karnauskas
    Department of Medicine, University of Chicago, IL 60637, USA
    Oncogene 22:688-98. 2003
    ..These results implicate activated Akt and growth-factor independence in leukemogenic transformation, and demonstrate the potential for in vivo analysis of genetic determinants of leukemogenesis...
  56. ncbi request reprint Bcl-x(L) complements Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to oxidative metabolism
    Matthew G Vander Heiden
    Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    J Biol Chem 277:44870-6. 2002
    ..Further characterization of the genes identified in this screen may enhance our understanding of Bcl-x(L) function in mammalian cells, and of cell survival pathways in general...
  57. doi request reprint Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases
    Frank P Vendetti
    Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, David H Koch Cancer Research Building 2, Room 562, 1550 Orleans Street, Baltimore, MD 21231, USA
    Expert Opin Biol Ther 13:1273-85. 2013
    ..Two key levels of aberrant epigenetic control are DNA methylation and histone acetylation. Primary regulators of these epigenetic changes include DNA methyltransferases (DNMTs) and histone deacetylases (HDACs)...
  58. pmc Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis
    Phuoc T Tran
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland, United States of America
    PLoS Genet 8:e1002650. 2012
    ..Hence, TWIST1 is a critical regulator of cellular senescence programs, and the suppression of TWIST1 in human tumors may be an effective example of pro-senescence therapy...
  59. ncbi request reprint An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia
    Charles M Rudin
    Medical Center, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    J Clin Oncol 21:4546-52. 2003
    ..The current study sought to establish the feasibility and activity of ONYX-015 administered topically as a mouthwash to patients with clinically apparent and histologically dysplastic lesions of the oral mucosa...
  60. ncbi request reprint Human Alu element retrotransposition induced by genotoxic stress
    Christy R Hagan
    Biological Sciences Division and Committee on Cancer Biology, University of Chicago, Chicago, Illinois 60637, USA
    Nat Genet 35:219-20. 2003
    ..We report that Alu retrotransposition can be induced in mouse cells by exposure to the topoisomerase II inhibitor etoposide and is mediated in trans by endogenous mouse long interspersed elements (LINEs)...
  61. ncbi request reprint Mobile genetic element activation and genotoxic cancer therapy: potential clinical implications
    Christy R Hagan
    Committee on Cancer Biology and Department of Medicine, University of Chicago, 5841 Aouth Maryland Avenue, Chicago, IL 60637, USA
    Am J Pharmacogenomics 2:25-35. 2002
    ..Understanding the cellular responses to genotoxic stress may permit the development of a means of predicting the risks and preventing the development of secondary malignancy following cancer therapy...
  62. pmc Geographic proximity and racial disparities in cancer clinical trial participation
    Norma F Kanarek
    Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Natl Compr Canc Netw 8:1343-51. 2010
    ..Clinical trial accruals are not uniform across age, sex, race, place of residence, cancer site, or trial type, underscoring that cancer centers must better understand their source patients to enhance clinical trial participation...
  63. doi request reprint Skin deep and deeper: multiple pathways in basal cell carcinogenesis
    Craig D Peacock
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, David H Koch Cancer Research Building, Room 546, 1550 Orleans Street, Baltimore, MD 21231, USA
    Cancer Prev Res (Phila) 3:1213-6. 2010
    ..both raise questions about the cell of origin for basal cell cancers and define additional putative therapeutic and preventive targets for this disease...
  64. doi request reprint Aberrant epigenetic regulation
    Rosalyn A Juergens
    From the Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD
    Am Soc Clin Oncol Educ Book 2013:295-300. 2013
    ..This manuscript will review the data on the role of epigenetics in lung cancer and the history of epigenetic treatments in lung cancer spanning over the last 40 years...
  65. ncbi request reprint Genotoxic exposure is associated with alterations in glucose uptake and metabolism
    Rixin Zhou
    Department of Medicine and the Committee on Cancer Biology, University of Chicago, Illinois 60637, USA
    Cancer Res 62:3515-20. 2002
    ..Mitochondrial responses to the resulting rapid decrease in metabolic substrates may play an important role in initiation of apoptotic cell death...
  66. pmc A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 2:638-44. 2007
    ..We undertook this phase II study to measure postoperative drug delivery and toxicity of cisplatin plus docetaxel in patients with resected stage I-III non-small cell lung cancer...
  67. pmc A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma
    Helen J Ross
    Thoracic Oncology Program, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, 5F40 Portland, OR 97213, United States
    Lung Cancer 54:69-77. 2006
    ..This Phase II, open-label study was conducted to confirm the activity of SGN-15 plus docetaxel in previously treated NSCLC patients...
  68. ncbi request reprint Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer
    Paul Ritch
    Milwaukee Medical College, Milwaukee, USA
    Lung Cancer 52:173-80. 2006
    ..The addition of aprinocarsen to gemcitabine+carboplatin therapy in patients with NSCLC showed moderate activity. However, this combination resulted in severe thrombocytopenia in the majority of patients...
  69. ncbi request reprint Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies
    Anatoly Dritschilo
    Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20007
    Clin Cancer Res 12:1251-9. 2006
    ..In this dose escalation study, we evaluated the safety of combined liposomal formulation of raf antisense oligonucleotide (LErafAON) and radiation therapy in patients with advanced malignancies...
  70. ncbi request reprint Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection
    Christopher M Carthy
    Department of Pathology and Laboratory Medicine, University of British Columbia St Paul s Hospital, The iCAPTUR4E Centre McDonald Research Laboratories, 1081 Burrard Street, Vancouver, British Columbia, Canada V6Z 1Y6
    Virology 313:147-57. 2003
    ..Our data suggest that mitochondrial release of cytochrome c may be an important early event in caspase activation in CVB3 infection, and, as such, may contribute to the loss of host-cell viability and progeny virus release...

Research Grants4

  1. Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small
    CHARLES RUDIN; Fiscal Year: 2007
    ..If successful, this approach could alter the poor prognosis of individuals with this disease. ..
  2. GENETIC AND GENOMIC RESPONSES TO DNA DAMAGE
    CHARLES RUDIN; Fiscal Year: 2002
    ..Understanding the molecular basis of the various cellular responses to DNA damage is relevant to the design of both chemopreventative and therapeutic anticancer strategies. ..
  3. A pharmacogenetic and pharmacodynamic study of erlotinib
    CHARLES RUDIN; Fiscal Year: 2004
    ..Defining the basis of this toxicity could also promote the development of EGFR-directed agents that may avoid such toxicity or that may be effective in a broader spectrum of cancer patients. ..